This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Migraine is the second most common and disabling disease worldwide,1 and some of the associated disability can be attributed to complications of the disease. Status migrainosus, whereby an attack exceeds 72 hours in duration,2 is a complication of migraine that has historically been very understudied. It is unclear how common it is, given limited data, but the few existing prevalence studies have estimated that anywhere from 3% to 20% of people with migraine may experience status migrainosus.3-5 What little evidence is available suggests that it is a considerable public health problem; it is associated with significant disability,5 and people with status migrainosus have a worse migraine prognosis5 and a higher risk of suicide6 when compared with people with migraine who do not experience status migrainosus. People with status migrainosus are also frequently hospitalized for management,4,5 and admissions are incredibly costly, with estimates varying between ∼USD $3,800 and 7,000 per admission.7,8 Unfortunately, existing inpatient therapies have very low levels of evidence to support their use and may have low efficacy rates.9
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
See page 114
- Received August 26, 2022.
- Accepted in final form September 12, 2022.
- © 2022 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
